Stupp regimen
Radiotherapy + Concomitant and Maintenance Temozolomide for Glioblastoma
Patient / Population Intervention / Exposure Comparison Outcome
In 573 patients with newly diagnosed glioblastoma, radiotherapy + concurrent and maintenance temozolomide improved overall survival compared with radiotherapy alone.
N
573
Design
Open-label RCT
Endpoint
Overall survival
Relevance
1
ResultOS 14.6 vs 12.1 months (HR 0.63). 2-yr OS 26.5% vs 10.4%; 5-yr OS 9.8% vs 1.9%. MGMT-methylated subgroup: OS 21.7 vs 15.3 months.
Stupp R, et al. N Engl J Med. 2005;352(10):987-996; Stupp R, et al. Lancet Oncol. 2009;10(5):459-466. 10.1056/NEJMoa043330
Discussion & critique
Remains the backbone of GBM therapy two decades later. MGMT methylation is the defining predictive biomarker; tumour-treating fields (EF-14) is the only later addition with class-I evidence.